KMT2B Gene: A Promising Target for MLL (G9757)

Target Name: KMT2B

NCBI ID: G9757

KMT2B

KMT2B Gene: A Promising Target for MLL

Mixed lineage leukemia (MLL) is a type of cancer that affects the bone marrow and blood cells. It is a type of leukemia that arises from a mistake in the DNA code, leading to the production of abnormal white blood cells. MLL is a serious and often fatal form of cancer, and there is currently no cure.

The KMT2B gene is a gene that is found on chromosome 9 and is known as the Mixed Lineage Leukemia Gene Homolog 2. It is a non-coding RNA molecule that is made up of about 1,800 base pairs of DNA. The KMT2B gene is located in the MLL gene cluster, which is a group of genes that are found on chromosome 9 and are involved in the development and treatment of MLL.

One of the things that makes the KMT2B gene so interesting as a potential drug target is its location in the MLL gene cluster. This means that scientists and doctors may be able to use the KMT2B gene as a biomarker to diagnose and monitor the progress of MLL. They may also be able to use it as a target for drugs that can treat MLL.

In addition to its potential as a drug target, the KMT2B gene is also of interest to researchers because of its role in the development of MLL. Studies have shown that the KMT2B gene is often expressed in MLL cells, and that it is involved in the formation of MLL leukemia cells. This suggests that targeting the KMT2B gene may be a way to treat or even cure MLL.

Another potential use for the KMT2B gene is as a diagnostic tool. Because the KMT2B gene is located in the MLL gene cluster, it is possible that researchers may be able to use it as a genetic fingerprint to diagnose MLL. This would be a powerful tool for diagnosing MLL, as it would allow doctors to quickly and accurately identify patients with this difficult-to-treat cancer.

In conclusion, the KMT2B gene is a promising candidate as a drug target for MLL. Its location in the MLL gene cluster and its involvement in the development of MLL make it an attractive target for researchers and doctors. While more research is needed to fully understand the potential of the KMT2B gene as a drug, it is clear that it has the potential to be a valuable tool in the fight against MLL.

Protein Name: Lysine Methyltransferase 2B

Functions: Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:25561738, PubMed:17707229). Likely plays a redundant role with KMT2C in enriching H3K4me1 marks on primed and active enhancer elements (PubMed:24081332). Plays a central role in beta-globin locus transcription regulation by being recruited by NFE2 (PubMed:17707229). Plays an important role in controlling bulk H3K4me during oocyte growth and preimplantation development (By similarity). Required during the transcriptionally active period of oocyte growth for the establishment and/or maintenance of bulk H3K4 trimethylation (H3K4me3), global transcriptional silencing that preceeds resumption of meiosis, oocyte survival and normal zygotic genome activation (By similarity)

The "KMT2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KMT2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets